Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 19;14(10):3554.
doi: 10.3390/jcm14103554.

Renal Denervation After USA FDA Approval: An Update from an Interventional Cardiologist's Perspective

Jiandong Zhang  1 , Peter M Belford  1 , George A Stouffer  2   3
Affiliations
Review

Renal Denervation After USA FDA Approval: An Update from an Interventional Cardiologist's Perspective

Jiandong Zhang et al. J Clin Med. .

Abstract

In late 2023, the U.S. Food and Drug Administration (FDA) approved two renal denervation (RDN) systems for the treatment of hypertension. Several professional societies, including the Society of Cardiovascular Angiography and Intervention (SCAI), the American Heart Association (AHA), and numerous European associations, have recognized the potential role of RDN in managing hypertension. Despite widespread enthusiasm from clinicians, patients, and the industry, the American Medical Association's Current Procedural Terminology (CPT) panel rejected the introduction of new codes for renal denervation at its September 2024 meeting. This article analyzes the latest evidence from clinical trials and registries, reviews current challenges in clinical practice, and explores the role of contemporary hypertension treatment from the perspective of interventional cardiologists.

Keywords: hypertension; renal denervation; resistant hypertension; sympathetic nervous system.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Key Steps in Identifying Responders to RDN.
See this image and copyright information in PMC

References

    1. Martin S.S., Aday A.W., Almarzooq Z.I., Anderson C.A.M., Arora P., Avery C.L., Baker-Smith C.M., Barone Gibbs B., Beaton A.Z., Boehme A.K., et al. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation. 2024;149:e347–e913. doi: 10.1161/CIR.0000000000001209. - DOI - PMC - PubMed
    1. Hardy S.T., Jaeger B.C., Foti K., Ghazi L., Wozniak G., Muntner P. Trends in Blood Pressure Control among US Adults With Hypertension, 2013–2014 to 2021–2023. Am. J. Hypertens. 2025;38:120–128. doi: 10.1093/ajh/hpae141. - DOI - PMC - PubMed
    1. Esler M.D., Osborn J.W., Schlaich M.P. Sympathetic Pathophysiology in Hypertension Origins: The Path to Renal Denervation. Hypertension. 2024;81:1194–1205. doi: 10.1161/HYPERTENSIONAHA.123.21715. - DOI - PubMed
    1. Zintel H.A., Mackie J.A., Sellers A.M., Jeffers W.A., Hafkenschiel J.H., Lindauer M.A. Results of thoracolumbar sympathectomy for essential hypertension; three-to-seven-year follow-up of one hundred patients. AMA Arch. Surg. 1955;71:215–222. doi: 10.1001/archsurg.1955.01270140063011. - DOI - PubMed
    1. Bhatt D.L., Kandzari D.E., O’Neill W.W., D’Agostino R., Flack J.M., Katzen B.T., Leon M.B., Liu M., Mauri L., Negoita M., et al. A controlled trial of renal denervation for resistant hypertension. N. Engl. J. Med. 2014;370:1393–1401. doi: 10.1056/NEJMoa1402670. - DOI - PubMed

LinkOut - more resources